Keyphrases
Phase II Study
100%
Antifolate
100%
Pemetrexed Disodium
100%
LY231514
100%
Advanced Colorectal Carcinoma
100%
Confidence Interval
40%
Overall Response Rate
20%
Anemia
20%
Neutropenia
20%
Safety Profile
20%
Nonhematologic
20%
Pharmacokinetics
20%
Blood Samples
20%
Median Time
20%
Adjuvant Therapy
20%
Colon
20%
Skin Reactions
20%
Complete Response
20%
Partial Response
20%
Intravenous Infusion
20%
Thrombocytopenia
20%
Median Survival
20%
Rectal Carcinoma
20%
Stable Disease
20%
Hematologic
20%
Common Toxicity Criteria
20%
Survival Time
20%
Transaminases
20%
Myelosuppression
20%
Time to Progression
20%
Folate Deficiency
20%
Colorectal Carcinoma
20%
Efficacy Analysis
20%
Metastatic Colorectal Adenocarcinoma
20%
Vitamin Metabolites
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pemetrexed
100%
Colorectal Carcinoma
100%
Folic Acid Antagonist
100%
Dexamethasone
20%
Anemia
20%
Neutropenia
20%
Thrombocytopenia
20%
Aminotransferase
20%
Survival Time
20%
Bone Marrow Suppression
20%
Skin Manifestation
20%
Rectum Carcinoma
20%
Folic Acid Deficiency
20%
Pharmacokinetics
20%
Diseases
20%